25 results on '"Sakamoto, N."'
Search Results
2. Clinical phase 1b study results for safety, pharmacokinetics and efficacy of ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 SIRNA for the treatment of Japanese patients with advanced liver fibrosis
3. Risk assessment of hepatocellular carcinoma in chronic liver disease patients with a combination of liver stiffness measurement and controlled attenuation parameter by FibroScan
4. Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C
5. Hepatitis B virus infected cell slows down its cell cycle and proliferation by viral protein and replication
6. Sustained virologic response by ledipasvir/sofosbuvir reduces the incidence of hepatocellular carcinoma in Japanese patients with HCV genotype 1 infection. - Comparison with Simeprevir with peginterferon plus ribavirin
7. FRI-406 - Changes in liver steatosis and lipid metabolism accompanied by successful interferon-free DAAs therapy in HCV infected patients; a comprehensive analysis
8. FRI-186 - Risk assessment of hepatocellular carcinoma in chronic liver disease patients with a combination of liver stiffness measurement and controlled attenuation parameter by FibroScan
9. THU-257 - Clinical phase 1b study results for safety, pharmacokinetics and efficacy of ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 SIRNA for the treatment of Japanese patients with advanced liver fibrosis
10. P0786 : 100% SVR12 with ledipasvir/sofosbuvir±ribavirin for 12 weeks in Japanese patients with chronic genotype 1 hepatitis C virus who previously failed therapy with protease inhibitor + pegylated interferonα + ribavirin
11. 1035 HEAT SHOCK FACTOR 1 ACCELERATES HEPATOCELLULAR CARCINOMA DEVELOPMENT BY ACTIVATING NUCLEAR FACTOR κB/MITOGEN-ACTIVATED PROTEIN KINASE
12. 441 THE ITPA GENOTYPE CORRELATES WITH HEMOLYTIC ANEMIA AND OUTCOME AFTER TREATMENT WITH PEGYLATED-INTERFERON AND RIBAVIRIN IN GENOTYPE IB CHRONIC HEPATITIS C
13. 469 ITPA GENE VARIANT PROTECTS AGAINST TREATMENT-INDUCED ANEMIA AND IMPROVES VIRAL CLEARANCE BY PEGYLATED INTERFERON-ALFA AND RIBAVIRIN THERAPY IN CHRONIC HEPATITIS C PATIENTS
14. 457 EZETIMIBE IMPROVES EFFICACY OF PEGIFN AND RIBAVIRIN THERAPY VIA ACCELERATION OF IFN-MEDIATED ISG15 CONJUGATION SYSTEM
15. 1178 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES IL28B ASSOCIATED WITH RESPONSE TO PEGYLATED INTERFERON-ALFA AND RIBAVIRIN THERAPY FOR JAPANESE PATIENTS WITH CHRONIC HEPATITIS C
16. 661 COMPARISON OF HCV-ASSOCIATED GENE EXPRESSION AND CELL SIGNALING PATHWAYS IN CELLS WITH OR WITHOUT HCV REPLICON AND IN REPLICON-CURED CELLS
17. 270 PREDICTIVE MODEL OF RESPONSE TO PEGINTERFERON IN CHRONIC HEPATITIS C: IMPACT OF MUTATIONS IN ISDR AND CORE REGION REVEALED BY CLASSIFICATION AND REGRESSION TREE ANALYSIS
18. 1169 GENETIC POLYMORPHISM IN IL28B PREDICTS NULL VIROLOGICAL RESPONSE TO PEGYLATED-INTERFERON PLUS RIBAVIRIN THERAPY FOR CHRONIC HEPATITIS C
19. Detection and analysis of replicating hepatitis C virus RNA in hepatocellular carcinoma tissues
20. Detection and quantification of hepatitis C virus RNA replication in the liver
21. Detection of hepatitis C viral RNA in sporadic acute non-A, non-B hepatitis by polymerase chain reaction. Its usefulness for the early diagnosis of seronegative infection
22. Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
23. Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.
24. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
25. The hypervariable region of the HCV genome changes sequentially during the progression of acute HCV infection to chronic hepatitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.